Quick answer
Two bodies of trial evidence exist for saffron and mood, and they answer two different questions. In adults diagnosed with major depression, a 2013 meta-analysis of five randomized trials found saffron beat placebo by a large statistical margin and performed similarly to antidepressant drugs in head-to-head trials — in small, short studies conducted mostly in Iran, a caveat the authors state themselves [SF01]. In healthy adults who reported low mood but had no diagnosis, a 2017 trial of 128 people found a standardized saffron extract at 28 mg a day improved mood and stress scores over four weeks, while 22 mg a day did not [SF02]. If you are a healthy reader with an everyday low mood, the second study is the one about you — promising, dose-specific and preliminary. If you have, or suspect, depression: that is medical territory, supplements are not the treatment, and if low mood persists beyond a couple of weeks, impairs your functioning, or ever includes thoughts of harming yourself, please contact a professional promptly (US: call or text 988). The pillar guide keeps the whole map; this article is the evidence, read closely.
Key takeaways
- Hausenblas 2013 [SF01]: 5 RCTs in diagnosed depression; effect size vs placebo 1.62 (large); vs antidepressants −0.15 (statistically indistinguishable); trial quality scores high (mean Jadad 5); authors demand larger, longer, non-Iranian trials before firm conclusions.
- Kell 2017 [SF02]: 128 healthy adults with self-reported low mood; affron® 28 mg/day × 4 weeks significantly reduced negative mood (POMS Total Mood Disturbance, p<0.001, effect size −1.10); 22 mg/day showed no significant effect — dose specificity is a finding, not a detail.
- Effect sizes measure group averages on rating scales, not whether any individual will feel different — and neither trial tested our product, or any unstandardized extract [SF-L01].
- The honest one-line summary of the whole field: real signal, small literature, short horizons, concentrated geography, some industry-linked extracts — worth taking seriously, not worth overselling.
Pile one, closely: the depression trials
The Hausenblas meta-analysis pooled every randomized, double-blind trial it could find of saffron for depressive symptoms up to 2013 [SF01]. Five trials qualified: two against placebo, three against standard antidepressants (fluoxetine and imipramine were the comparators in this literature). Participants were adults with major depressive disorder — diagnosed patients, in clinical settings, rated on clinician scales like the Hamilton Depression Rating Scale.
The headline numbers: saffron versus placebo produced a mean effect size of 1.62 — in statistical terms, large; the average treated participant improved more than roughly 95% of the placebo group on symptom scores. Saffron versus antidepressants produced −0.15, which is statistical noise: in these small trials, the spice and the drugs landed in the same place. Trial quality, scored by the Jadad scale (randomization, blinding, dropouts), averaged 5 of 5 — as rigorous as small trials get.
Now the limits, in the authors' own spirit: five trials is a small literature; most came from one research region (Iran, where saffron is both a crop and a traditional medicine — and where most of the world's saffron research groups sit); durations were weeks, not the months or years over which depression actually lives; and publication bias — positive small trials publish more easily than negative ones — can inflate pooled effects in any young field. None of that erases the signal. All of it forbids the sentence "saffron works as well as antidepressants" from appearing in marketing copy, including ours. What the pile supports, precisely: saffron is one of the most credibly trialled botanicals in mood research, in diagnosed populations, pending bigger replication.
Pile two, closely: the healthy-adult trial
Kell and colleagues asked the question that matches most supplement shoppers [SF02]: not "can it treat illness?" but "does it help healthy people who feel low?" They recruited 128 adults who self-reported low mood and screened out diagnosed depression, then randomized them to a standardized saffron extract (affron®, made from saffron stigmas and standardized to its active Lepticrosalides) at 28 mg/day, the same extract at 22 mg/day, or placebo, for four weeks. Mood was measured with the Profile of Mood States (POMS), a standard self-report instrument.
Results: the 28 mg group showed a significant decrease in negative mood and in stress- and anxiety-related symptoms versus placebo — on the POMS Total Mood Disturbance scale, p<0.001 with an effect size of −1.10. The 22 mg group did not significantly separate from placebo. Two readings matter here. First, the dose threshold: whatever saffron does, in this trial it had a floor below which nothing measurable happened — a standing warning against "a little saffron in a blend" products. Second, the limits the authors note: screening and outcomes were self-reported, the sample was self-selected, four weeks is short, and the extract was a specific commercial preparation — findings belong to that extract at that dose, not to saffron in general and emphatically not to any unstandardized capsule [SF-L01].
A word about the placebo groups
In the depression trials, placebo groups improved too — substantially, as placebo groups in mood research reliably do. That is not fakery: expectation, regular contact with caring researchers, the natural ebb of an episode and regression to the mean all move symptom scores, and they are part of why a control group exists at all. Saffron's job in those trials was to beat that whole bundle, and in the pooled analysis it did [SF01]. Keep the same lens for any personal experiment: if you start a supplement the week you also fix your sleep and start walking again, improvement has several honest authors — which is fine for your life, as long as the supplement doesn't take sole credit in your head or in our copy.
What an effect size can't tell you
Both piles report group statistics. An effect size of −1.10 on a mood scale means the average score moved a lot relative to the spread of scores; it does not mean every participant felt better, that you would, or that the change maps to anything a clinician would call recovery. Rating scales in healthy volunteers also start near the floor — there is only so much "less negative" available — which cuts both ways: real movement is harder to manufacture, and easier to over-read. This is why the library's verbs are support and studied, never works in the testimonial sense. It is also why your own trial of any mood supplement deserves structure: one change at a time, four-plus weeks, notes kept — the same discipline the caffeine audit in our hydration library teaches.
Frequently asked questions
So is saffron an antidepressant?
No. It is a botanical that has been tested in antidepressant trials with results that justify more research [SF01]. Antidepressants are regulated medicines prescribed for a diagnosed illness; if you take one, changing anything about your regimen is your prescriber's call — including adding saffron, which touches serotonin pathways and belongs in that conversation first.
Which study should I believe — the depression one or the healthy one?
Both, for their own populations. The error is importing the depression trials' drama into a healthy reader's expectations (or the reverse). If nobody has diagnosed you with anything and your mood is simply low, Kell 2017 is your reference point [SF02]: modest literature, one good trial, dose-specific.
Does the brand of extract matter?
In the trials, the extract was the intervention — standardized preparations with declared actives [SF02]. Our own label declares 88.5 mg of extract with no standardization percentage [SF-L01], so the trial results cannot be assumed to transfer. Judge any saffron product by what its label declares; the dose article in this library shows the full comparison.
How long were people on it before effects showed?
Four weeks in the healthy-adult trial [SF02], typically six to eight in the depression trials [SF01]. Saffron is a slow, cumulative story in the data — the opposite of a rescue remedy.
What don't we know yet?
Whether effects persist past a few months, whether results replicate at scale outside the original research groups, how saffron compares with other supports head-to-head in healthy people, and the long-term safety picture at supplement doses. The field is promising and young; both halves of that sentence are the finding.
Next step
Mechanisms next — why a flower's pigments might touch mood at all, and which parts of that story are animal data wearing human clothes: How Saffron Works. Then the real-life group of this library takes over, starting with the most important article we will publish this year: knowing the line between low mood and depression.
References
[SF01] Hausenblas HA et al. — Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials (Journal of Integrative Medicine, 2013; PMID 24299602): 5 RCTs in adults with MDD (2 placebo-controlled, 3 antidepressant-controlled); effect size vs placebo 1.62 (p<0.001); vs antidepressants −0.15 (similar efficacy); mean Jadad score 5; authors call for larger trials outside Iran with long-term follow-up: https://pubmed.ncbi.nlm.nih.gov/24299602/
[SF02] Kell G et al. — affron®, a novel saffron extract (Crocus sativus L.), improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial (Complementary Therapies in Medicine, 2017; PMID 28735826): 128 healthy adults self-reporting low mood (not diagnosed); 28 mg/day significantly reduced negative mood and stress/anxiety symptoms (POMS TMD p<0.001, d=−1.10); 22 mg/day no significant effect; self-report limitations noted by authors: https://pubmed.ncbi.nlm.nih.gov/28735826/
• Recommended Products:
.
Cart (
